BioSpace News Archive

Biotech Beach

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA ® Approval in Fireside Chat at the Annual Conference of the American Urological Association.

April 30, 2024
·
8 min read
Drug Development

Arsenal Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of AB-2100 in Development as a Treatment for Clear-cell Renal Cell Carcinoma

Arsenal Biosciences, Inc. today announced that the first patient has been dosed with AB-2100 in a multi-center, open-label Phase 1/2 clinical trial for patients with clear-cell renal cell carcinoma (ccRCC).

April 30, 2024
·
3 min read
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Holding Corporation announces that the National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute has awarded a $3.6 million grant for a clinical trial to evaluate the Selective Cytopheretic Device Adult (SCD-ADULT.

April 30, 2024
·
8 min read
FDA

Ingenium Therapeutics Novel NK Cell Therapy Receives Orphan Drug Designation From FDA

Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, announced today that its investigational therapy IGNK001 (Gengluecel) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

April 30, 2024
·
2 min read
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Silence Therapeutics plc today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference.

April 30, 2024
·
1 min read
BioMidwest

Neogen® Launches New Molecular Method for Detection of Two Salmonella Serotypes

Neogen® Corporation announced the launch of the new Neogen Molecular Detection Assay 2 – Salmonella Enteritidis/Salmonella Typhimurium.

April 30, 2024
·
3 min read
Drug Development

Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression

Nacuity Pharmaceuticals, Inc. today announced that the first patients have been implanted in the final cohort of the Phase 1/2 clinical trial evaluating NPI-002 for delayed cataract progression in patients undergoing vitrectomy.

April 30, 2024
·
3 min read
Pharm Country

FDA clears first fully autonomous AI for portable diabetic retinopathy screening

AEYE Health, the leading company for AI retinal imaging and diagnostics, is thrilled to announce that it received the first ever FDA clearance for a fully autonomous AI that diagnoses referable diabetic retinopathy from retinal images obtained by a handheld camera.

April 30, 2024
·
4 min read
Business

Genomics plc and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design

Genomics plc and GSK announced a new collaboration to explore the potential for using polygenic risk scores in clinical trials, to improve understanding of disease risk and patient selection, which could support optimisation of trial design.

April 30, 2024
·
2 min read
Drug Development

Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis

Renovion Inc., a biopharmaceutical company focused on developing therapies to restore lung health in individuals with mucus-related lung diseases, announced topline results of the Phase 2 CLIMB study of ARINA-1 in individuals with non-CF bronchiectasis (NCFBE).

April 30, 2024
·
7 min read